Dr. Helfand on how genomic testing provides real-time status of prostate tumor

Around the Practice

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”

Related Videos
Around the Practice July 21, 2021: Bladder Cancer Cases
Genetic, Genomic Testing in Heavily Treated, Metastatic Castrate-Resistant Prostate Cancer
Genetic, Genomic Testing in Newly Diagnosed, High-Grade, High-Risk Prostate Cancer
Around the Practice
metastatic castrate resistant prostate cancer
Around the Practice
Related Content

Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer

May 6th 2021

Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer

May 6th 2021

Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer

May 6th 2021
© 2023 MJH Life Sciences

All rights reserved.